EP1912939A1 - Metabotropic glutamate-receptor-potentiating isoindolones - Google Patents
Metabotropic glutamate-receptor-potentiating isoindolonesInfo
- Publication number
- EP1912939A1 EP1912939A1 EP06720758A EP06720758A EP1912939A1 EP 1912939 A1 EP1912939 A1 EP 1912939A1 EP 06720758 A EP06720758 A EP 06720758A EP 06720758 A EP06720758 A EP 06720758A EP 1912939 A1 EP1912939 A1 EP 1912939A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- alkyl
- group
- alkylnr
- cycloalkyl
- alkylaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- the present invention relates to novel compounds that function as potentiators of glutamate receptors, methods for their preparation, pharmaceutical compositions containing them and their use in therapy.
- the metabotropic glutamate receptors are a family of GTP -binding-protein (G-protein) coupled receptors that are activated by glutamate, and that have important roles in synaptic activity in the central nervous system, neural plasticity, neural development and neurodegeneration.
- Activation of mGluRs in intact mammalian neurons elicits one or more of the following responses: activation of phospholipase C; increases in phosphoinositide (PI) hydrolysis; intracellular calcium release; activation of phospholipase D; activation or inhibition of adenyl cyclase; increases or decreases in the formation of cyclic adenosine monophosphate (cAMP); activation of guanylyl cyclase; increases in the formation of cyclic guanosine monophosphate (cGMP); activation of phospholipase A 2 ; increases in arachidonic acid release; and increases or decreases in the activity of voltage- and ligand-gated ion channels (Schoepp et al, 1993, Trends Pharmacol.
- PI phosphoinositide
- Group-I includes mGluRl and mGluR5, which activate phospholipase C and the generation of an intracellular calcium signal.
- Group-II mGluR2 and niGluR3
- Group-Ill mGluR4, rnGluR ⁇ , mGluR7, and mGluR8
- mGluRs mediate an inhibition of adenylyl cyclase activity and cyclic AMP levels.
- mGluR family receptors Activity of mGluR family receptors is implicated in a number of normal processes in the mammalian CNS, and are important targets for compounds for the treatment of a variety of neurological and psychiatric disorders. Activation of mGluRs is required for induction of hippocampal long-term potentiation and cerebellar long-term depression (Bashir et ah, 1993, Nature, 363:347 ; Bortolotto et a!., 1994, Nature, 368:740 ; Aiba et al., 1994, Cell, 79:365 ; Aiba et ah, 1994, Cell, 79:377).
- mGluR activation has been suggested to play a modulatory role in a variety of other normal processes including synaptic transmission, neuronal development, apoptotic neuronal death, synaptic plasticity, spatial learning, olfactory memory, central control of cardiac activity, waking, motor control and control of the vestibulo-ocular reflex (Nakanishi, 1994, Neuron, 13:1031; Pin et ah, 1995, Neuropharmacology, see above; Knopfel et al., 1995, J. Med. Chem., 38:1417).
- R 1 is a 3- to 7-membered ring that may contain one or more heteroatoms independently selected from the group consisting of N, O and S, wherein said ring is substituted by one or more B;
- R 2 and R 3 are independently selected from the group consisting of H, Ci -6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, aryl, heteroaryl, heterocycloalkyl, Cs.g-cycloalkyl, Ci -6 -alkyl-aryl, Ci -6 -alkyl-heteroaryl, and Ci- ⁇ -alkyl-Cs-s-cycloalkyl, wherein R and R 3 may be substituted by one or more A;
- R 4 and R 6 are independently selected from the group consisting of H, hydroxy, F, Cl, Br, I, nitro, cyano, Ci -6 -alkyl, Q-e-alkylhalo, OCi -6 alkyl, OCi -6 -alkylhalo, C 2-6 -alkenyl, OC 2 - 6 -alkenyl, C 2 - 6 -alkynyl, OC 2-6 -alkynyl, C ⁇ s-cycloalkyl, Ci -6 -alkyl-C 3-8 -cycloalkyl, OC 0-6 -alkyl-C 3-8 ⁇ cycloalkyl, aryl, C 1-6 -alkylaryl, OC 0 .
- 6 -alkylCO 2 R 10 d-e-alkylcyano, OC 2- 6-alkylcyano, C 0-6 -alkylNR 10 R ⁇ , OC 2 - 6 -alkylNR 10 R ⁇ , C 1 . 6 -alkyl(CO)NR 10 R 11 , OC 1-6 -alkyl(CO)NR 10 R 11 , C 0-6 -alkylNR 10 (CO)R n , OC 2-6 -alkylNR 10 (CO)R 11 , Co -6 -alkylNR 10 (CO)NR 10 R ⁇ , C 0 .
- R 5 is selected from the group consisting of H, F, Cl, Br, I, nitro, CN, Ci_ 6 -alkyl, OCo -6 -alkyl, Ci_ 6 -alkylhalo, OC 1-6 -alkylhalo, C 2-6 -alkenyl, OC 2-6 -alkenyl, C 2-6 -alkynyl, OC 2 - 6 -alkynyl, C 3 _ 8 -cycloalkyl, Ci-e-alkyl-Cs-s-cycloalkyl, OC 0-6 -alkyl-C 3-8 -cycloalkyl, aryl, Ci- 6 -alkylaryl, C 1-6 -alkylheteroaryl, OCi -6 -alkylaryl, OC 1-6 -alkylheteroaryl, Ci- ⁇ -alkylheterocycloalkyl, Oheterocycloalkyl, OQ
- R 7 is selected from the group consisting of H, F, Cl, Br, I, nitro, cyano, OCi -4 -alkyl, Ci -6 -alkyl, C 1-6 -alkylhalo, OCi -6 -alkylhalo, C 2-6 -alkenyl, OC 2-6 -alkenyl, C 2-6 -alkynyl, OC 2-6 -alkynyl, and C 3-8 -cycloalkyl;
- R 8 and R 9 are independently selected from the group consisting of H, F, Cl, Br, I, nitro, cyano, C 1-6 -alkyl, C 1-6 -alkylhalo, OC 1-6 alkyl, OCi -6 -alkylhalo, C 2-6 -alkenyl,
- R 1 and R l are independently selected from the group consisting of H, hydroxy, oxo, F, Cl, Br, I, nitro, cyano, C 1-6 -alkyl, Ci -6 -alkylhalo, OCi -6 alkyl, OCi- 6 -alkylhalo, C 2-6 -alkenyl, OC 2-6 -alkenyl, C 2-6 -alkynyl, OC 2-6 -alkynyl, C 3-8 -cycloalkyl, Ci -6 -alkyl-C 3-8 -cycloalkyl, OC 0-6 -alkyl-C 3-8 -cycloalkyl, aryl, C 1-6 -alkylaryl, OC 0-6 -alkylaryl, Co- ⁇ -alkyl-heterocycloalkyl, OCj- ⁇ -alkyl-heterocycloalkyl, heteroaryl, and Ci -6 alkylheter
- A is selected from the group consisting of H, hydroxy, F, Cl, Br, I, nitro, cyano, oxo, Ci -6 -alkyl, Ci -6 -alkylhalo, OC 1-6 alkyl, OCi -6 -alkylhalo, C 2-6 -alkenyl, OC 2-6 -alkenyl, C 2-6 -alkynyl, OC 2-6 -alkynyl, C 3-8 -cycloalkyl, C 1-6 -alkyl-C 3-8 -cycloalkyl, OCo- ⁇ -alkyl-Cs-s-cycloalkyl, aryl, Ci -6 -alkylaryl, OCo -6 -alkylaryl, d- ⁇ -alkyl-heterocyclyl, Ci-e-alkyl-heterocycloalkyl, OC 0-6 -alkyl-heterocycloalkyl, (CO
- B is selected from the group consisting of C 3-8 -cycloalkyl, C 1-6 -alkyl-C 3- g-cycloalkyl, OCo- ⁇ -alkyl-C B -s-cycloalkyl, C 0-6 -alkylaryl, OC 0-6 -alkylaryl, Ci- ⁇ -alkyl-heterocycloalkyl, C 1-6 -alkyl-heterocycloalkyl, OCo- ⁇ -alkyl-heterocycloalkyl, C 0-6 -alkyl-heteroaryl and OC 0-6 -alkyl-heteroaryl, wherein any cyclic moiety is substituted with at least one substituent selected from the group consisting of halo, alkyl, alkylhalo, hydroxy, alkoxy, oxo, COR, CO 2 R, SO 2 R and CN; and n is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7,
- the invention also provides processes for the preparation of compounds of formula I.
- the invention further provides a pharmaceutical composition comprising a compound according to formula I together with a pharmaceutically acceptable carrier or excipient; in another aspect the invention provides a method for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction in an animal in need of such treatment.
- the method comprises the step of administering to the animal a therapeutically effective amount of a compound of formula I or a pharmaceutical composition thereof.
- the invention also provides for the use of a compound according to formula I, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for the treatment of any of the conditions discussed herein. Further, the invention provides a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, for use in therapy.
- the present invention is based upon the discovery of compounds that exhibit activity as modulators of metabotropic glutamate receptors. More particularly, the compounds of the present invention exhibit activity as potentiators of the mGluR2 receptor, and are useful in therapy, in particular as pharmaceuticals for the treatment of neurological and psychiatric disorders associated with glutamate dysfunction.
- alkyl as used herein means a straight- or branched-chain hydrocarbon radical having, for example, from one to six carbon atoms, and includes methyl, ethyl, propyl, isopropyl, t-butyl and the like.
- alkenyl as used herein means a straight- or branched-chain alkenyl radical having, for example, from two to six carbon atoms, and includes ethenyl, 1 -propenyl, 1-butenyl and the like.
- alkynyl as used herein means a straight- or branched-chain alkynyl radical having, for example, from two to six carbon atoms, and includes 1-propynyl (propargyl), 1-butynyl and the like.
- cycloalkyl as used herein means a cyclic group (which may be unsaturated) having, for example, from three to seven carbon atoms, and includes cyclopropyl, cyclohexyl, cyclohexenyl and the like.
- heterocycloalkyl as used herein means, for example, a three- to seven-membered cyclic group (which may be unsaturated) having at least one heteroatom selected from the group consisting of N, S and O, and includes piperidinyl, piperazinyl, pyrrolidinyl, tetrahydrofuranyl and the like.
- alkoxy as used herein means a straight- or branched-chain alkoxy radical having, for example, from one to six carbon atoms and includes methoxy, ethoxy, propyloxy, isopropyloxy, t-butoxy and the like.
- halo as used herein means halogen and includes fluoro, chloro, bromo, iodo and the like, in both radioactive and non-radioactive forms.
- aryl as used herein means an aromatic group having, for example, five to twelve atoms, and includes phenyl, naphthyl and the like.
- heteroaryl means an aromatic group which includes at least one heteroatom selected from the group consisting of N, S and O, and includes groups and includes pyridyl, indolyl, furyl, benzofuryl, thienyl, benzothienyl, quinolyl, oxazolyl and the like.
- alkanoyl as used herein means a straight- or branched-chain alkanoyl radical having, for example, from two to seven atoms, and includes acetyl, propionyl, butyryl and the like.
- cycloalkenyl as used herein means an unsaturated cylcloaklyl group having, for example, from four to seven carbon atoms, and includes cyclopent-1-enyl, cyclohex-1-enyl and the like.
- alkylaryl refers to an alkyl radical substituted with an aryl, heteroaryl or cycloalkyl group, and includes 2-phenethyl, 3 -cyclohexyl propyl and the like.
- the term "5- to 7-membered ring that may contain one or more heteroatoms independently selected from N, O and S” includes aromatic and heteroaromatic rings, as well as carbocyclic and heterocyclic rings which may be saturated or unsaturated, and includes furyl, isoxazolyl, oxazolyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidyl, pyrrolyl, thiazolyl, thienyl, imidazolyl, triazolyl, morpholinyl, piperazinyl, piperidinyl, homopiperidinyl, tetrahydropyranyl, phenyl, cyclohexyl, cycloheptyl, cyclopentyl, cyclohexanyl and the like.
- pharmaceutically acceptable salt means either an acid addition salt or a basic addition salt which is compatible with the treatment of patients.
- a "pharmaceutically acceptable acid addition salt” is any non-toxic organic or inorganic acid addition salt of the base compounds represented by Formula I or any of its intermediates.
- Illustrative inorganic acids which form suitable salts include hydrochloric, hydrobromic, sulfuric and phosphoric acid and acid metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate.
- Illustrative organic acids which form suitable salts include the mono-, di- and tricarboxylic acids.
- Illustrative of such acids are, for example, acetic, glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, hydroxymaleic, benzoic, hydroxybenzoic, phenylacetic, cinnamic, salicylic, 2-phenoxybenzoic, p-toluenesulfonic acid and other sulfonic acids such as methanesulfonic acid and 2-hydroxyethanesulfonic acid.
- Either the mono- or di-acid salts can be formed, and such salts can exist in either a hydrated, solvated or substantially anhydrous form.
- the acid addition salts of these compounds are more soluble in water and various hydrophilic organic solvents, and generally demonstrate higher melting points in comparison to their free base forms.
- the selection criteria for the appropriate salt will be known to one skilled in the art.
- Other non-pharmaceutically acceptable salts e.g. oxalates may be used for example in the isolation of compounds of Formula I for laboratory use, or for subsequent conversion to a pharmaceutically acceptable acid addition salt.
- a "pharmaceutically acceptable basic addition salt” is any non-toxic organic or inorganic base addition salt of the acid compounds represented by Formula I or any of its intermediates.
- Illustrative inorganic bases which form suitable salts include lithium, sodium, potassium, calcium, magnesium or barium hydroxides.
- Illustrative organic bases which form suitable salts include aliphatic, alicyclic or aromatic organic amines such as methylamine, trimethyl amine and picoline or ammonia.
- the selection of the appropriate salt may be important so that an ester functionality, if any, elsewhere in the molecule is not hydrolyzed. The selection criteria for the appropriate salt will be known to one skilled in the art.
- Solvate means a compound of Formula I or the pharmaceutically acceptable salt of a compound of Formula I wherein molecules of a suitable solvent are incorporated in a crystal lattice.
- a suitable solvent is physiologically tolerable at the dosage administered as the solvate. Examples of suitable solvents are ethanol, water and the like. When water is the solvent, the molecule is referred to as a hydrate.
- stereoisomers is a general term for all isomers of the individual molecules that differ only in the orientation of their atoms in space. It includes mirror image isomers (enantiomers), geometric (cis/trans) isomers and isomers of compounds with more than one chiral centre that are not mirror images of one another (diastereomers).
- treat or “treating” means to alleviate symptoms, eliminate the causation of the symptoms either on a temporary or permanent basis, or to prevent or slow the appearance of symptoms of the named disorder or condition.
- terapéuticaally effective amount means an amount of the compound which is effective in treating the named disorder or condition.
- pharmaceutically acceptable carrier means a non-toxic solvent, dispersant, excipient, adjuvant or other material which is mixed with the active ingredient in order to permit the formation of a pharmaceutical composition, i.e., a dosage form capable of administration to the patient.
- a pharmaceutical composition i.e., a dosage form capable of administration to the patient.
- a pharmaceutically acceptable oil typically used for parenteral administration.
- R 1 is a 3- to 7-membered ring that may contain one or more heteroatoms independently selected from the group consisting of N, O and S, wherein said ring is substituted by one or more B;
- R 2 and R 3 are independently selected from the group consisting of H, Ci -6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, aryl, heteroaryl, heterocycloalkyl, C 3-8 -cycloalkyl, Ci -6 -alkyl-aryl, Ci_ 6 -alkyl-heteroaryl, Ci_ 6 -alkyl-heterocycloalkyl, and Ci -6 -alkyl-C 3-8 -cycloalkyl, wherein R 2 and R 3 may be substituted by one or more A;
- R 4 and R 6 are independently selected from the group consisting of H, hydroxy, F, Cl, Br, I, nitro, cyano, C 1-6 -alkyl, Ci -6 -alkylhalo, OC 1-6 alkyl, OCi -6 -alkylhalo, C 2-6 -alkenyl, OC2-6-alkenyl, C 2-6 -alkynyl, OC 2-6 -alkynyl, C 3-8 -Cy cloalkyl, Ci- ⁇ -alkyl-Cs.s-cycloalkyl, OCo -6 -alkyl-C 3-8 -cycloalkyl, aryl, C 1-6 -alkylaryl, OC 0-6 -alkylaryl, (CO)R 10 , O(CO)R 10 , 0(CO)OR 10 , C(O)OR 10 , O(CNR 10 )OR n , C 1-6 -alkylOR 10
- R 5 is selected from the group consisting of H, F, Cl, Br, I, nitro, CN, Ci -6 -alkyl, OCo -6 -alkyl, C 1-6 -alkylhalo, OC 1-6 -alkylhalo, C 2-6 -alkenyl, OC 2-6 -alkenyl, C 2-6 -alkynyl, OC 2-6 -alkynyl, C 3 .g-cycloalkyl, Ci- ⁇ -alkyl-Cs-s-cycloalkyl, OCo-o-alkyl-Cs-s-cycloalkyl, aryl, Cj -6 -alkylaryl, C 1-6 -alkylheteroaryl, OC 1-6 -alkylaryl, OC 1-6 -alkylheteroaryl, Ci- ⁇ -alkylheterocycloalkyl, Oheterocycloalkyl, OC ⁇ -alkylhe
- R 7 is selected from the group consisting of H, F, Cl, Br, I, nitro, cyano, OCi -4 -alkyl, Ci- 6 -alkyl, C 1-6 -alkylhalo, OCi -6 -alkylhalo, C 2-6 -alkenyl, OC 2-6 -alkenyl, C 2-6 -alkynyl, OC 2-6 -alkynyl, and C 3 -s-cycloalkyl; o Q
- R and R are independently selected from the group consisting of H, F, Cl, Br, I, nitro, cyano, C 1-6 -alkyl, C 1-6 -alkylhalo, OC 1-6 alkyl, OC 1-6 -alkylhalo, C 2-6 -alkenyl, OC 2-6 -alkenyl, C 2-6 -alkynyl, and OC 2-6 -alkynyl, or, where n is greater than 1 , two or more R and/or R 9 on adjacent carbon atoms may be absent to form an alkenyl or alkynyl moiety;
- R 10 and R 11 are independently selected from the group consisting of H, hydroxy, oxo, F, Cl, Br, I, nitro, cyano, C 1-6 -alkyl, Ci -6 -alkylhalo, OC 1-6 alkyl, OCi -6 -alkylhalo, C 2-6 -alkenyl, OC 2-6 -alkenyl, C 2-6 -alkynyl, OC 2-6 -alkynyl, C 3-8 -cycloalkyl, Ci -6 -alkyl-C 3- g-cycloalkyl, OCo- 6 -alkyl-Cs-s-cycloalkyl, aryl, Ci- 6 -alkylaryl, OC 0-6 -alkylaryl, Co-e-alkyl-heterocycloalkyl, OCi- ⁇ -alkyl-heterocycloalkyl, heteroaryl, and Ci -6 alkylheteroary
- A is selected from the group consisting of H, hydroxy, F, Cl, Br, I, nitro, cyano, oxo, C 1-6 -alkyl, C 1-6 -alkylhalo, OCi -6 alkyl, OCi -6 -alkylhalo, C 2-6 -alkenyl, OC 2-6 -alkenyl, C 2-6 -alkynyl, OC 2-6 -alkynyl, C 3-8 -cycloalkyl, C 1-6 -alkyl-C 3-8 -cycloalkyl, OC 0-6 -alkyl-C 3-8 -cycloalkyl, aryl, C 1-6 -alkylaryl, OC 0-6 -alkylaryl, Cj-e-alkyl-heterocyclyl, Ci-e-alkyl-heterocycloalkyl, OCo-e-alkyl-heterocycloalkyl, (CO)
- B is selected from the group consisting of C ⁇ s-cycloalkyl, Ci -6 -alkyl-C 3-8 -cycloalkyl, OC 0-6 -alkyl-C 3- 8-cycloalkyl, C 0-6 -alkylaryl, OC 0-6 -alkylaryl, Ci-e-alkyl-heterocycloalkyl, OCo- ⁇ -alkyl-heterocycloalkyl, C 0-6 -alkyl-heteroaryl and OCo -6 -alkyl-heteroaryl, wherein any cyclic moiety is substituted with at least one substituent selected from the group consisting of halo, alkyl, alkylhalo, hydroxy, alkoxy, oxo, COR, CO 2 R, SO 2 R and CN, and n is selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, and 8; or a pharmaceutically acceptable salt, hydrate, solvate, optical is
- R 1 is phenyl wherein said phenyl is substituted by one or more B;
- R 2 and R 3 are independently selected from the group consisting of H, Ci -6 -alkyl, C 2-6 -alkenyl, C 2-6 -alkynyl, aryl, heteroaryl, heterocycloalkyl, C 3-8 -cycloalkyl, Ci -6 -alkyl-aryl, C 1-6 -alkyl-heteroaryl, Ci-e-alkyl-heterocycloalkyl, and C 1-6 -alkyl-C 3-8 -cycloalkyl, wherein R 2 and R 3 may be substituted by one or more A; R 4 and R 6 are independently selected from the group consisting of H 5 hydroxy, F, Cl, Br, I, nitro, cyano, Ci -6 -alkyl, Ci -6 -alkylhalo, OCi.
- R 5 is selected from the group consisting of H, F, Cl, Br, I, nitro, CN, Ci -6 -alkyl, OCo- 6 -alkyl, Ci- 6 -alkylhalo, OC 1-6 -alkylhalo, C 2-6 -alkenyl, OC 2-6 -alkenyl, C 2-6 -alkynyl, OC 2-6 -alkynyl, C 3-8 -cycloalkyl, OC 0-6 -alkyl-C 3-8 -cycloalkyl, aryl, C 1-6 -alkylaryl, Ci -6 -alkylheteroaryl, OC 1-6 -alkylaryl, OC 1-6 -alkylheteroaryl, Ci- ⁇ -alkylheterocycloalkyl, Oheterocycloalkyl, OCi-e-alkylheterocycloalkyl, C(O)H, (CO)R
- R 7 is selected from the group consisting of H, F, Cl, Br, I, nitro, cyano, OCi -4 -alkyl, Ci -6 -alkyl, Ci -6 -alkylhalo, OC 1-6 -alkylhalo, C 2-6 -alkenyl, OC 2-6 -alkenyl, C 2-6 -alkynyl, OC 2-6 -alkynyl, and C 3-8 -cycloalkyl;
- R 8 and R 9 are both H
- R 10 and R 11 are independently selected from the group consisting of H, hydroxy, oxo, F, Cl, Br, I, nitro, cyano, Ci -6 -alkyl, Ci_ 6 -alkylhalo, OCi -6 alkyl, OCi -6 -alkylhalo, C 2-6 -alkenyl, OC 2-6 -alkenyl, C 2-6 -alkynyl, OC 2-6 -alkynyl, C 3-8 -cycloalkyl, Ci.
- any cyclic moiety is optionally fused to a 5- to 7-membered ring that may contain one or more heteroatoms independently selected from the group consisting of C, N, O and S and any cyclic moiety is optionally substituted with a substituent selected from alkyl, halo, hydroxyl, Oalkyl, haloalkyl and Ohaloalkyl;
- A is selected from the group consisting of H, hydroxy, F, Cl, Br, I, nitro, cyano, oxo, Ci -6 -alkyl, C 1-6 -alkylhalo, OC 1-6 alkyl, OCi -6 -alkylhalo, C 2-6 -alkenyl, OC 2-6 -alkenyl, C 2-6 -alkynyl, OC 2-6 -alkynyl, C 3 _ 8 -cycloalkyl, C 1-6 -alkyl-C 3-8 -cycloalkyl, OC 0-6 -alkyl-C 3- 8-cycloalkyl, aryl, Ci_ 6 -alkylaryl, OC 0-6 -alkylaryl, Ci-e-alkyl-heterocycloalkyl, OCce-alkyl-heterocycloalkyl, (CO)R 10 , O(CO)R 10 , 0(CO)OR
- B is selected from the group consisting of C 0-6 -alkylaryl and OC 0-6 -alkylaryl, wherein any aryl moiety is substituted with at least one substituent selected from the group consisting of halo, alkyl, alkylhalo, hydroxy, alkoxy, oxo, COR, CO 2 R, SO 2 R and CN; and n is 1; or a pharmaceutically acceptable salt, hydrate, solvate, optical isomer, or combination thereof.
- R 1 is phenyl wherein said phenyl is substituted by one or more B;
- R 2 and R 3 are independently selected from the group consisting of H and C 1-6 -alkyl
- R 4 is H and R 6 is selected from the group consisting of H, hydroxy, F, Cl, Br, I, nitro, cyano, C 1-6 -alkyl, and OCi -6 alkyl;
- R 5 is selected from the group consisting of H, F, Cl, Br, I, or a 5- to 7-membered ring that may contain one or more heteroatoms independently selected from the group consisting of N, O and S;
- R 7 is selected from the group consisting of H or C 1-6 -alkyl
- R 8 and R 9 are both H
- B is OCo -6 -alkylaryl, wherein said aryl moiety is substituted with at least one substituent selected from the group consisting of halo, alkyl, alkylhalo and alkoxy, and n is 1; or a pharmaceutically acceptable salt, hydrate, solvate, optical isomer, or combination thereof.
- R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and n are defined as hereinabove.
- n is 1, 2, or 3.
- R 8 and R on adjacent carbon atoms can be missing so as to form partially or fully unsaturated moieties.
- n is 1 and two adjacent R and R are missing, the moiety is an alkenyl group.
- R 8 and R 9 are missing, the moiety is an alkynyl group. All of these combinations are contemplated.
- n is 1.
- R and R particularly are each H.
- R is a 5- to 7-membered ring that is selected from the group consisting of aryl, C 3-8- cycloalkyl, cycloalkenyl, and heterocyclyl optionally substituted by one or more A selected from the group consisting of F, Cl, Br, I 5 OCi -6 -alkylhalo, and OC 0-6 -alkylaryl.
- Exemplary rings in this context include but are not limited to phenyl, naphthyl, C 3-8- cycloalkyl, cycloalkenyl, furanyl, tetrahydrofuranyl, thiophenyl, pyridyl, oxadiazolyl, quinolinyl, piperazinyl, and tetrahydropyranyl.
- R 1 is phenyl optionally substituted by one or more A selected from the group consisting of F, Cl, Br, I 5 OCi -6 -alkylhalo, and OC 0-6 -alkylaryl.
- R 1 is phenyl optionally substituted by one or more A selected from the group consisting of F, Cl, Br, I, OC 1-6 -alkylhalo, and OC 0-6 -alkylaryl.
- R 2 , R 3 , R 4 , R 6 , R 8 , and R 9 are each H and n is 1.
- Particular values for R 7 include H, Cl, Br, I, C 1-6 -alkyl, and OC 1-4 -alkyl, particularly H, Cl, Br, I, -CH 3 , and -OCH 3 , and most particularly Cl 5 Br 5 I, and -OCH 3 .
- R 1 is a C 3-8 -cycloalkyl group. Particularly, R 1 is cyclopropyl. In this embodiment, n is particularly 1, 2, or 3, and most particularly is 1.
- R 5 is selected from the group consisting of C 3-8 -cycloalkyl, Ci -6 -alkyl-C 3-8 -cycloalkyl, OC 0-6 -alkyl-C 3-8 -cycloalkyl, aryl, C 1-6 -alkylaryl, OC 1-6 -alkylaryl, and a 5- to 7-membered ring that may contain one or more heteroatoms independently selected from the group consisting of N, O and S.
- R 5 may be substituted by one or more A, and any cycloalkyl or aryl is optionally fused to a 5- to 7-membered ring that may contain one or more heteroatoms independently selected from the group consisting of C, N, O and S.
- R 5 is selected from Ci_ 6 -alkylaryl and a 5- to 7-membered ring that may contain one or more heteroatoms independently selected from the group consisting of N, O and S, wherein R may be substituted by one or more A.
- R 5 is a 5- to 7-membered ring that may contain one or more heteroatoms independently selected from the group consisting of N, O and S, which ring is substituted by one or more A selected from the group consisting of Ci- 6 -alkyl-heterocyclyl and a 5- to 7-membered ring that may contain one or more heteroatoms independently selected from the group consisting of N, O and S.
- n is 1, 2, or 3;
- R 4 , R 6 , R 8 and R 9 are each H;
- R 1 is selected from the group consisting of aryl, C 3-8- cycloalkyl, cycloalkenyl, and heterocyclyl optionally substituted by one or more A selected from the group consisting of F 5 Cl, Br, I, OC t - 6 -alkylhalo, and OC 0-6 -alkylaryl;
- R 7 is selected from the group consisting of H, Cl, Br, I, C 1-6 -alkyl, and OCi_ 4 -alkyl, and
- R 5 is selected from the group consisting of C 3- g-cycloalkyl, C 1-6 -alkyl-C 3-8 -cycloalkyl, OCo -6 -alkyl-C 3-8 -cycloalkyl, aryl, C 1-6 -alkylaryl, OCi -6 -alkylaryl, and
- n is 1, 2, or 3;
- R 4 , R 6 , R 8 and R 9 are each H;
- R 1 is selected from phenyl, naphthyl, C 3-8- cycloalkyl, cycloalkenyl, furanyl, tetrahydrofuranyl, thiophenyl, pyridyl, oxadiazolyl, quinolinyl, piperazinyl, and tetrahydropyranyl optionally substituted by one or more A selected from the group consisting of F, Cl, Br, I, OCi -6 -alkylhalo, and OC 0-6 -alkylaryl;
- R 7 is selected from Cl, Br, I, and -OCH 3
- R 5 is selected from C 1-6 -alkylaryl and a 5- to 7-membered ring that may contain one or more heteroatoms independently selected from the group consisting of N, O and S, wherein R 5 may be substituted by one or more
- n is 1, 2, or 3;
- R 4 , R 6 , R 8 and R 9 are each H;
- R 1 is phenyl optionally substituted by one or more A selected from the group consisting of F, Cl, Br, I, OC 1-6 -alkylhalo, and OCo -6 -alkylaryl;
- R 7 is selected from the group consisting of H, Cl, Br, I, C 1-6 -alkyl, and OC 1-4 -alkyl, and
- R 5 is a 5- to 7-membered ring that may contain one or more heteroatoms independently selected from the group consisting of N, O and S, wherein the 5- to 7-membered ring is substituted by one or more A selected from the group consisting of Ci- 6 -alkyl-heterocyclyl and a 5- to 7-membered ring that may contain one or more heteroatoms independently selected from the group consisting of N, O and S.
- n is 1 ;
- R 2 , R 3 , R 4 , R 6 , R 8 and R 9 are each H;
- R 1 is phenyl optionally substituted by one or more A selected from the group consisting of F, Cl, Br, I, OCi -6 -alkylhalo, and OC 0-6 -alkylaryl;
- R 7 is selected from Cl, Br, I, and -OCH 3 , and
- R 5 is selected from C 1-6 -alkylaryl and a 5- to 7-membered ring that may contain one or more heteroatoms independently selected from the group consisting of N, O and S, wherein R 5 may be substituted by one or more A.
- the compounds of the invention may exist in, and be isolated as, enantiomeric or diastereomeric forms, or as a racemic mixture.
- the present invention includes any possible enantiomers, diastereomers, racemates or mixtures thereof, of a compound of formula I.
- the optically active forms of the compound of the invention may be prepared, for example, by chiral chromatographic separation of a racemate, by synthesis from optically active starting materials or by asymmetric synthesis based on the procedures described thereafter.
- salts of the compounds of formula I are also salts of the compounds of formula I.
- pharmaceutically acceptable salts of compounds of the present invention are obtained using standard procedures well known in the art, for example, by reacting a sufficiently basic compound, for example an alkyl amine with a suitable acid, for example, HCl or acetic acid, to afford a physiologically acceptable anion.
- a corresponding alkali metal such as sodium, potassium, or lithium
- an alkaline earth metal such as a calcium
- a compound of the present invention having a suitably acidic proton, such as a carboxylic acid or a phenol with one equivalent of an alkali metal or alkaline earth metal hydroxide or alkoxide (such as the ethoxide or methoxide), or a suitably basic organic amine (such as choline or meglumine) in an aqueous medium, followed by conventional purification techniques.
- a suitably acidic proton such as a carboxylic acid or a phenol
- an alkali metal or alkaline earth metal hydroxide or alkoxide such as the ethoxide or methoxide
- a suitably basic organic amine such as choline or meglumine
- the compound of formula I may be converted to a pharmaceutically acceptable salt or solvate thereof, particularly, an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, methanesulphonate or j?-toluenesulphonate.
- an acid addition salt such as a hydrochloride, hydrobromide, phosphate, acetate, fumarate, maleate, tartrate, citrate, methanesulphonate or j?-toluenesulphonate.
- compositions include the compounds described herein, their pharmaceutically acceptable salts, hydrates, solvates and optical isomers thereof.
- the compounds of the present invention may be formulated into conventional pharmaceutical composition comprising a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof, in associaton with a pharmaceutically acceptable carrier or excipient.
- the pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include, but are not limited to, powders, tablets, dispersible granules, capsules, cachets, and suppositories.
- a solid carrier can be one or more substances, which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, or table disintegrating agents.
- a solid carrier can also be an encapsulating material.
- the carrier is a finely divided solid, which is in a mixture with the finely divided compound of the invention, or the active component.
- the active component is mixed with the carrier having the necessary binding properties in suitable proportions and compacted in the shape and size desired.
- a low-melting wax such as a mixture of fatty acid glycerides and cocoa butter is first melted and the active ingredient is dispersed therein by, for example, stirring. The molten homogeneous mixture is then poured into convenient sized moulds and allowed to cool and solidify.
- Suitable carriers include, but are not limited to, magnesium carbonate, magnesium stearate, talc, lactose, sugar, pectin, dextrin, starch, tragacanth, methyl cellulose, sodium carboxymethyl cellulose, low-melting wax, cocoa butter, and the like.
- composition is also intended to include the formulation of the active component with encapsulating material as a carrier providing a capsule in which the active component (with or without other carriers) is surrounded by a carrier which is thus in association with it. Similarly, cachets are included.
- Tablets, powders, cachets, and capsules can be used as solid dosage forms suitable for oral administration.
- Liquid form compositions include solutions, suspensions, and emulsions.
- sterile water or water propylene glycol solutions of the active compounds may be liquid preparations suitable for parenteral administration.
- Liquid compositions can also be formulated in solution in aqueous polyethylene glycol solution.
- Aqueous solutions for oral administration can be prepared by dissolving the active component in water and adding suitable colorants, flavoring agents, stabilizers, and thickening agents as desired.
- Aqueous suspensions for oral use can be made by dispersing the finely divided active component in water together with a viscous material such as natural synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose, and other suspending agents known to the pharmaceutical formulation art.
- Exemplary compositions intended for oral use may contain one or more coloring, sweetening, flavoring and/or preservative agents.
- the pharmaceutical composition will include from about 0.05%w (percent by weight) to about 99%w, more particularly, from about 0.10%w to 50%w, of the compound of the invention, all percentages by weight being based on the total weight of the composition.
- a therapeutically effective amount for the practice of the present invention can be determined by one of ordinary skill in the art using known criteria including the age, weight and response of the individual patient, and interpreted within the context of the disease which is being treated or which is being prevented.
- Neurological and psychiatric disorders amenable to treatment with compounds disclosed herein include, but are not limited to, disorders such as cerebral deficit subsequent to cardiac bypass surgery and grafting, stroke, cerebral ischemia, spinal cord trauma, head trauma, perinatal hypoxia, cardiac arrest, hypoglycemic neuronal damage, dementia (including AIDS-induced dementia), Alzheimer's disease, Huntington's disease, amyotrophic lateral sclerosis, ocular damage, retinopathy, cognitive disorders, idiopathic and drug-induced Parkinson's disease, muscular spasms and disorders associated with muscular spasticity including tremors, epilepsy, convulsions, cerebral deficits secondary to prolonged status epilepticus, migraine (including migraine headache), urinary incontinence, substance tolerance, substance withdrawal (including, substances such as opiates, nicotine, tobacco products, alcohol, benzodiazepines, cocaine, sedatives, hypnotics, etc.), psychosis, schizophrenia, anxiety (including generalized anxiety disorder, panic disorder, social phobia, obse
- the invention thus provides a use of any of the compounds according to formula I, or a pharmaceutically acceptable salt or solvate thereof, for the manufacture of a medicament for the treatment of any of the conditions discussed above.
- the invention provides a method for the treatment of a subject suffering from any of the conditions discussed above, whereby an effective amount of a compound according to formula I or a pharmaceutically acceptable salt or solvate thereof, is administered to a patient in need of such treatment.
- the invention also provides a compound of formula I or pharmaceutically acceptable salt or solvate thereof, as hereinbefore defined for use in therapy.
- the term “therapy” also includes “prophylaxis” unless there are specific indications to the contrary.
- the term “therapeutic” and “therapeutically” should be construed accordingly.
- the term “therapy” within the context of the present invention further encompasses the administration of an effective amount of a compound of the present invention, to mitigate either a pre-existing disease state, acute or chronic, or to mitigate a recurring condition.
- This definition also encompasses prophylactic therapies for prevention of recurring conditions and continued therapy for chronic disorders.
- the compounds of the present invention may be administered in the form of a conventional pharmaceutical composition by any route including orally, intramuscularly, subcutaneously, topically, intranasally, intraperitoneally, intrathoracially, intravenously, epidurally, intrathecally, intracerebroventricularly and by injection into the joints.
- the route of administration is oral, intravenous, or intramuscular.
- the dosage will depend on the route of administration, the severity of the disease, age and weight of the patient and other factors normally considered by the attending physician, who determines the individual regimen and dosage level for a particular patient.
- the compounds described herein may be provided or delivered in a form suitable for oral use, for example, in a tablet, lozenge, hard and soft capsule, aqueous solution, oily solution, emulsion, and suspension.
- the compounds may be formulated into a topical administration, for example, as a cream, ointment, gel, spray, or aqueous solution, oily solution, emulsion or suspension.
- the compounds described herein also may be provided in a form that is suitable for nasal administration, for example, as a nasal spray, nasal drops, or dry powder.
- the compounds can be administered to the vagina or rectum in the form of a suppository.
- the compounds described herein also may be administered parentally, for example, by intravenous, intravesicular, subcutaneous, or intramuscular injection or infusion.
- the compounds can be administered by insufflation (for example as a finely divided powder).
- the compounds may also be administered transdermally or sublingually.
- the compounds of formula I, or salts thereof are useful as pharmacological tools in the development and standardisation of in vitro and in vivo test systems for the evaluation of the effects of inhibitors of mGluR-related activity in laboratory animals as part of the search for new therapeutics agents.
- Such animals include, for example, cats, dogs, rabbits, monkeys, rats and mice. Processes for Preparing:
- a compound of formula Ib is then cross-coupled with a suitable reagent containing R to yield a a compound according to formula Ic:
- 5-substituted-7-methyl isoindolones are synthesized as depicted in Scheme 1 below.
- 4-bromo-2,6-dimethylaniline is converted to the corresponding nitrile under Sandmeyer reaction conditions.
- the nitrile is then hydrolyzed to the acid in a stepwise fashion.
- the amide can be obtained by basic hydrolysis.
- the amide is then diazotized and hydrolyzed with nitrososulphuric acid to provide the benzoic acid, which is subsequently protected as the methyl ester using standard conditions.
- the benzylic methyl group is monobrominated with N-bromosuccinimide using benzoyl peroxide as the radical initiator.
- 5-substituted-7-chloro isoindolones are synthesized as depicted in Scheme 2 below.
- 4-bromo-2-methylbenzoic acid is chlorinated ortho to the acid using N-chlorosuccinimide and a palladium catalyst.
- this acid was then esterified, brominated, and cyclized to yield the isoindolone intermediate.
- Substituent R 5 is introduced similarly.
- isoindolones that are substituted with an amide at C5 can be prepared as depicted in Scheme 3 below.
- an appropriately substituted 5-bromoisoindolone is converted to the corresponding nitrile using zinc cyanide in the presence of a palladium catalyst.
- the nitrile is then hydrolyzed under basic conditions to provide the benzoic acid, which was then coupled with various amines using methodologies that are well-known in the art to provide the final compounds.
- the pharmacological properties of the compounds of the invention can be analyzed using standard assays for functional activity.
- glutamate receptor assays are well known in the art as described in, for example, Aramori et ah, 1992, Neuron, 8:757; Tanabe et al, 1992, Neuron, 8:169; Miller etal, 1995, J. Neuroscience, 15:6103; Balazs, et al, 1997, J. Neurochemistry, 1997,69:151.
- the methodology described in these publications is incorporated herein by reference.
- the compounds of the invention can be studied by means of an assay that measures the mobilization of intracellular calcium, [Ca 2+ ] j in cells expressing mGluR2.
- Fluorometric Imaging Plate Reader FLIPR analysis was used to detect allosteric activators of mGluR2 via calcium mobilization.
- FLIPR Fluorometric Imaging Plate Reader
- the cells were trypsinized and plated in DMEM at 100,000 cells/well in black sided, clear-bottom, collagen I coated, 96-well plates. The plates were incubated under 5% CO 2 at 37 0 C overnight. Cells were loaded with 6 ⁇ M fluo-3 acetoxymethylester (Molecular Probes, Eugene Oregon) for 60 minutes at room temperature.
- FLIPR experiments were done using a laser setting of 0.8 W and a 0.4 second CCD camera shutter speed. Extracellular fluo-3 was washed off and cells were maintained in 160 ⁇ L of buffer and placed in the FLIPR. An addition of test compound (0.01 ⁇ M to 30 ⁇ M in duplicate) was made after 10 seconds of baseline fluorescent readings were recorded on FLIPR. Fluorescent signals were then recorded for an additional 75 seconds at which point a second addition of DCG-IV (0.2 ⁇ M) was made and fluorescent signals were recorded for an additional 65 seconds. Fluorescent signals were measured as the peak height of the response within the sample period. Data was analyzed using Assay Explorer, and EC 50 and E max values (relative to maximum DCG-IV effect) were calculated using a four parameter logistic equation.
- a [ 35 S]-GTPyS binding assay was used to functionally assay mGluR2 receptor activation.
- the allosteric activator activity of compounds at the human mGluR2 receptor were measured using a [ 35 S]-GTPyS binding assay with membranes prepared from CHO cells which stably express the human mGluR2.
- the assay is based upon the principle that agonists bind to G-protein coupled receptors to stimulate GDP-GTP exchange at the G-protein. Since [ 35 S]-GTPyS is a non-hydrolyzable GTP analog, it can be used to provide an index of GDP-GTP exchange and, thus, receptor activation.
- the GTPyS binding assay therefore provides a quantitative measure of receptor activation.
- Membranes were prepared from CHO cells stably transfected with human mGluR2. Membranes (30 ⁇ g protein) were incubated with test compound (3 nM to 300 ⁇ M) for 15 minutes at room temperature prior to the addition of 1 ⁇ M glutamate, and incubated for 30 min at 30 0 C in 500 ⁇ L assay buffer (20 mM HEPES, 100 mM NaCl, 10 raM MgCl 2 ), containing 30 ⁇ M GDP and 0.1 nM [ 35 S]-GTPyS (1250 Ci/mmol). Reactions were carried out in triplicate in 2 mL polypropylene 96-well plates.
- Example 1 5-Bromo-2-[4-(2-fluorophenoxy)benzyl]-7-methyl-2,3-dihydro-isoindol-l-one
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2005/028760 WO2006020879A1 (en) | 2004-08-13 | 2005-08-12 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
PCT/US2006/005246 WO2007021308A1 (en) | 2005-08-12 | 2006-02-15 | Metabotropic glutamate-receptor-potentiating isoindolones |
Publications (1)
Publication Number | Publication Date |
---|---|
EP1912939A1 true EP1912939A1 (en) | 2008-04-23 |
Family
ID=36464390
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06720759A Withdrawn EP1912940A1 (en) | 2005-08-12 | 2006-02-15 | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators |
EP06720758A Withdrawn EP1912939A1 (en) | 2005-08-12 | 2006-02-15 | Metabotropic glutamate-receptor-potentiating isoindolones |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP06720759A Withdrawn EP1912940A1 (en) | 2005-08-12 | 2006-02-15 | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators |
Country Status (4)
Country | Link |
---|---|
EP (2) | EP1912940A1 (en) |
JP (2) | JP2009509921A (en) |
CN (2) | CN101309905A (en) |
WO (2) | WO2007021308A1 (en) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7807706B2 (en) | 2005-08-12 | 2010-10-05 | Astrazeneca Ab | Metabotropic glutamate-receptor-potentiating isoindolones |
TWI417095B (en) | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mglur2-receptors |
US20080139846A1 (en) * | 2006-09-01 | 2008-06-12 | Astrazeneca Ab | New Process 298 |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
WO2008130853A1 (en) * | 2007-04-17 | 2008-10-30 | Astrazeneca Ab | Hydrazides and their use as metabotropic glutamate receptor potentiators - 681 |
EP2150244A1 (en) * | 2007-04-23 | 2010-02-10 | House Ear Institute | Treatment and/or prevention of presbycusis by modulation of metabotropic glutamate receptor 7 |
CN101687790B (en) | 2007-05-25 | 2015-02-11 | Abbvie公司 | Heterocyclic compounds as positive modulators of metabotropic glutamate receptor 2 (mglu2 receptor) |
TWI417100B (en) * | 2007-06-07 | 2013-12-01 | Astrazeneca Ab | Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators-842 |
TW200911255A (en) * | 2007-06-07 | 2009-03-16 | Astrazeneca Ab | Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841 |
WO2009004430A1 (en) * | 2007-06-29 | 2009-01-08 | Pfizer Inc. | N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors |
CN101801930B (en) | 2007-09-14 | 2013-01-30 | 奥梅-杨森制药有限公司 | 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones |
ATE496906T1 (en) | 2007-09-14 | 2011-02-15 | Ortho Mcneil Janssen Pharm | 1',3'-DISUBSTITUTED 4-PHENYL-3,4,5,6-TETRAHYDRO-2H,1'H-Ä1,4'ÜBIPYRI INYL-2'-ONE |
US7790760B2 (en) * | 2008-06-06 | 2010-09-07 | Astrazeneca Ab | Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286 |
GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
TW201006801A (en) | 2008-07-18 | 2010-02-16 | Lilly Co Eli | Imidazole carboxamides |
EP2344470B1 (en) | 2008-09-02 | 2013-11-06 | Janssen Pharmaceuticals, Inc. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
RU2517181C2 (en) | 2008-10-16 | 2014-05-27 | Орто-Макнейл-Янссен Фармасьютикалз, Инк. | Indole and benzomorpholine derivatives as modulator of metabotropic glutamate receptors |
BRPI0921333A2 (en) | 2008-11-28 | 2015-12-29 | Addex Pharmaceuticals Sa | indole and benzoxazine derivatives as metabotropic glutamate receptor modulators |
AU2010221980A1 (en) | 2009-03-11 | 2011-10-13 | Msd K.K. | Novel isoindolin-1-one derivative |
BRPI1010831A2 (en) | 2009-05-12 | 2016-04-05 | Addex Pharmaceuticals Sa | 1,2,4-triazolo [4,3-a] pyridine derivatives and their as positive allosteric modulators of mglur2 receptors |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
KR101753826B1 (en) | 2009-05-12 | 2017-07-04 | 얀센 파마슈티칼즈, 인코포레이티드 | 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders |
MY183201A (en) * | 2009-10-09 | 2021-02-18 | Celgene Corp | Processes for the preparation of 2-(1-phenylethyl)isoindolin-1-one compounds |
EP2496569A2 (en) | 2009-11-02 | 2012-09-12 | MSD Oss B.V. | Heterocyclic derivatives |
KR20120112749A (en) * | 2010-01-07 | 2012-10-11 | 아스트라제네카 아베 | Process for making a metabotropic glutamate receptor positive allosteric modulator - 874 |
US8314120B2 (en) | 2010-03-30 | 2012-11-20 | Abbott Gmbh & Co. Kg | Small molecule potentiators of metabotropic glutamate receptors |
US8664214B2 (en) | 2010-03-30 | 2014-03-04 | AbbVie Deutschland GmbH & Co. KG | Small molecule potentiators of metabotropic glutamate receptors I |
PT2649069E (en) | 2010-11-08 | 2015-11-20 | Janssen Pharmaceuticals Inc | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
JP5852666B2 (en) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of the mGluR2 receptor |
EP2643320B1 (en) | 2010-11-08 | 2015-03-04 | Janssen Pharmaceuticals, Inc. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
AR088320A1 (en) | 2011-10-14 | 2014-05-28 | Incyte Corp | ISOINDOLINONE AND PIRROLOPIRIDINONE DERIVATIVES AS AKT INHIBITORS |
WO2013063549A1 (en) | 2011-10-28 | 2013-05-02 | Vanderbilt University | Substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m1 |
JO3368B1 (en) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
JO3367B1 (en) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
CN109999025A (en) | 2014-01-21 | 2019-07-12 | 詹森药业有限公司 | Positive allosteric modulator or the combination of normotopia agonist including metabotropic glutamate energy receptor subtype 2 and application thereof |
NZ722385A (en) | 2014-01-21 | 2019-11-29 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
TWI713455B (en) | 2014-06-25 | 2020-12-21 | 美商伊凡克特治療公司 | Mnk inhibitors and methods related thereto |
GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
MX2018005204A (en) | 2015-10-29 | 2018-08-01 | Effector Therapeutics Inc | Isoindoline, azaisoindoline, dihydroindenone and dihydroazaindenone inhibitors of mnk1 and mnk2. |
CA3002558A1 (en) | 2015-10-29 | 2017-05-04 | Effector Therapeutics, Inc. | Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit mnk1 and mnk2 |
US10000487B2 (en) | 2015-11-20 | 2018-06-19 | Effector Therapeutics, Inc. | Heterocyclic compounds that inhibit the kinase activity of Mnk useful for treating various cancers |
CN105837557A (en) * | 2016-05-05 | 2016-08-10 | 青岛辰达生物科技有限公司 | Preparation method of alogliptin for treating type-II diabetes |
CN106279182B (en) * | 2016-07-29 | 2019-06-07 | 中国药科大学 | A kind of pyrrolo- [2,1-a] iso-indole ketone compounds and its synthetic method |
MX2019009653A (en) | 2017-02-14 | 2019-12-19 | Effector Therapeutics Inc | Piperidine-substituted mnk inhibitors and methods related thereto. |
GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
EP3459939A1 (en) * | 2017-09-26 | 2019-03-27 | Pragma Therapeutics | Novel heterocyclic compounds as modulators of mglur7 |
AU2019366947A1 (en) | 2018-10-24 | 2021-06-03 | Effector Therapeutics, Inc. | Crystalline forms of Mnk inhibitors |
US11396502B2 (en) | 2018-11-13 | 2022-07-26 | Incyte Corporation | Substituted heterocyclic derivatives as PI3K inhibitors |
US11161838B2 (en) | 2018-11-13 | 2021-11-02 | Incyte Corporation | Heterocyclic derivatives as PI3K inhibitors |
WO2020102198A1 (en) | 2018-11-13 | 2020-05-22 | Incyte Corporation | Heterocyclic derivatives as pi3k inhibitors |
CN110498759A (en) * | 2019-09-12 | 2019-11-26 | 天津瑞岭化工有限公司 | The synthetic method of isoindoline ketone compound |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE620654C (en) * | 1933-04-29 | 1935-10-24 | Smith & Sons Ltd S | Speed indicator |
US3579524A (en) * | 1968-06-05 | 1971-05-18 | Miles Lab | 2-aminoalkyl derivatives of phthalimidines |
US3993617A (en) * | 1975-10-30 | 1976-11-23 | Morton-Norwich Products, Inc. | Antifungal 2-substituted phthalimidines |
DE3717561A1 (en) * | 1987-05-25 | 1988-12-08 | Thomae Gmbh Dr K | INDOL, ISOCHINOLINE AND BENZAZEPINE DERIVATIVES, MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF |
JPH02184667A (en) * | 1989-01-11 | 1990-07-19 | Meiji Seika Kaisha Ltd | N-n'-di-substituted piperazyl derivative and dysuria-improving agent containing the same |
TW219935B (en) * | 1991-12-25 | 1994-02-01 | Mitsubishi Chemicals Co Ltd | |
US5681954A (en) * | 1993-05-14 | 1997-10-28 | Daiichi Pharmaceutical Co., Ltd. | Piperazine derivatives |
RU2124511C1 (en) * | 1993-05-14 | 1999-01-10 | Фармасьютикал Ко., Лтд | Piperazine derivatives |
CN1554649A (en) * | 1997-11-21 | 2004-12-15 | NPSҩ������˾ | Metabotropic glutamate receptor antagonists for treating central nervous system diseases |
AU3417501A (en) * | 2000-02-29 | 2001-09-12 | Mitsubishi Tokyo Pharm Inc | Novel cyclic amide derivatives |
DE10031391A1 (en) * | 2000-07-03 | 2002-02-07 | Knoll Ag | Bicyclic compounds and their use for the prophylaxis and therapy of cerebral ischemia |
DE60130766T2 (en) * | 2000-07-18 | 2008-07-17 | Dainippon Sumitomo Pharma Co., Ltd. | SEROTONIN RECOVERY INHIBITORS |
DE10238865A1 (en) * | 2002-08-24 | 2004-03-11 | Boehringer Ingelheim International Gmbh | New carboxamides are melanin-concentrating hormone receptor antagonists, useful for treating e.g. metabolic diseases, diabetes, eating disorders, cardiovascular disease, emotional disorders, reproductive and memory disorders |
GB0223232D0 (en) * | 2002-10-07 | 2002-11-13 | Pfizer Ltd | Chemical compounds |
WO2005040157A2 (en) * | 2003-10-22 | 2005-05-06 | Eli Lilly And Company | Novel mch receptor antagonists |
US20080275062A1 (en) * | 2004-01-30 | 2008-11-06 | David Harold Drewry | Chemical Compounds |
JP4883296B2 (en) * | 2004-03-05 | 2012-02-22 | 日産化学工業株式会社 | Isoxazoline-substituted benzamide compounds and pest control agents |
JPWO2005085214A1 (en) * | 2004-03-05 | 2008-01-17 | 萬有製薬株式会社 | Diaryl-substituted hetero 5-membered ring derivatives |
TW200613272A (en) * | 2004-08-13 | 2006-05-01 | Astrazeneca Ab | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators |
-
2006
- 2006-02-15 CN CNA2006800353774A patent/CN101309905A/en active Pending
- 2006-02-15 JP JP2008525977A patent/JP2009509921A/en active Pending
- 2006-02-15 EP EP06720759A patent/EP1912940A1/en not_active Withdrawn
- 2006-02-15 EP EP06720758A patent/EP1912939A1/en not_active Withdrawn
- 2006-02-15 CN CNA2006800363117A patent/CN101277934A/en active Pending
- 2006-02-15 WO PCT/US2006/005246 patent/WO2007021308A1/en active Application Filing
- 2006-02-15 JP JP2008525976A patent/JP5031745B2/en not_active Expired - Fee Related
- 2006-02-15 WO PCT/US2006/005247 patent/WO2007021309A1/en active Application Filing
Non-Patent Citations (1)
Title |
---|
See references of WO2007021308A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP1912940A1 (en) | 2008-04-23 |
WO2007021309A1 (en) | 2007-02-22 |
JP5031745B2 (en) | 2012-09-26 |
WO2007021308A1 (en) | 2007-02-22 |
CN101277934A (en) | 2008-10-01 |
JP2009509921A (en) | 2009-03-12 |
JP2009509920A (en) | 2009-03-12 |
CN101309905A (en) | 2008-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1912939A1 (en) | Metabotropic glutamate-receptor-potentiating isoindolones | |
US7868008B2 (en) | Substituted isoindolones and their use as metabotropic glutamate receptor potentiators | |
US8153638B2 (en) | Metabotropic glutamate-receptor-potentiating isoindolones | |
TWI417100B (en) | Oxadiazole derivatives and their use as metabotropic glutamate receptor potentiators-842 | |
US20110053953A1 (en) | AZA-Isoindolones and Their Use as Metabotropic Glutamate Receptor Potentiators - 613 | |
WO2008130853A1 (en) | Hydrazides and their use as metabotropic glutamate receptor potentiators - 681 | |
JP5031565B2 (en) | Isoindole compounds and their use as metabotropic glutamate receptor potentiators | |
JP5608655B2 (en) | Modulator of P2X3 receptor activity | |
DE69929704T2 (en) | TETRAHYDROBENZAZEPINE DERIVATIVES USE AS DOPAMINE D3 RECEPTOR MODULATORS (ANTIPSYCHOTIC AGENTS) | |
EP2061775A2 (en) | Spiro-oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | |
JP2009519929A (en) | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | |
JP2010520876A (en) | Piperazine and piperidine mGluR5 potentiator | |
JP2009503069A (en) | Tricyclic benzimidazoles and their use as modulators of metabolic glutamate receptors | |
JP2009532381A (en) | Bicyclic benzimidazole compounds and use of the compounds as metabotropic glutamate receptor potentiators | |
MX2010012357A (en) | Amide compound. | |
JP2010529117A (en) | Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators | |
JP2006523707A (en) | Therapeutic compound | |
JP2009536213A (en) | Fused heterocyclic compounds and their use as MGLUR5 modulators | |
DE60305332T2 (en) | IMIDAZOi1,2-AöPYRIDINE |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR |
|
17P | Request for examination filed |
Effective date: 20080201 |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: VAN WAGENEN, BRADFORD Inventor name: UKKIRAMAPANDIAN, RADHAKRISHNAN Inventor name: URBANEK, REBECCA, C/O ASTRAZENECA WILMINGTON Inventor name: ISAAC, METHVIN Inventor name: MA, FUPENG Inventor name: WALSH, SALLY, C/O ASTRAZENECA WILMINGTON Inventor name: SLASSI, ABDELMALIK Inventor name: CLAYTON, JOSHUA Inventor name: STEELMAN, GARY, ASTRAZENECA WILMINGTON Inventor name: EGLE, IAN Inventor name: EMPFIELD, JAMES, C/O ASTRAZENECA WILMINGTON |
|
DAX | Request for extension of the european patent (deleted) | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1113157 Country of ref document: HK |
|
17Q | First examination report despatched |
Effective date: 20110908 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20150214 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1113157 Country of ref document: HK |